I

Intuitive Surgical

Manufactures robotic surgical systems and services

Staff Biostatistician

Full-Time
$162.7k - $260.1k/yr+ Incentives + Equity
Senior, Expert
Master's, PhD
Sunnyvale, CA, USA
RemotePreference will be given to candidates who can work onsite in Sunnyvale or are willing to relocate. Up to 10% travel is required.

About the job

Requirements
  • A Master's (MS) or Ph.D. in Biostatistics or Statistics is required.
  • At least 9 years of professional experience with a Master's degree, or 6 years with a Ph.D., is required.
  • At least 5 years of clinical trial experience is required.
  • At least 5 years of medical device experience is required.
  • Demonstrated development and application of innovative biostatistical methodology to complex problems, with depth in several of the following: adaptive and group-sequential designs, Bayesian methods, historical or external controls, survival and longitudinal modeling, hierarchical models, multiplicity control, missing data and sensitivity analysis, and analysis of large real-world datasets.
  • Mastery of R is required.
  • Demonstrated ability to set programming standards, write clean modular and well-tested code, and lead code review and validation practices in a shared development environment.
  • Fluency in Git in a GxP-validated environment for reproducible, regulatory-compliant analyses is required.
  • Proven experience applying frontier artificial intelligence models to redesign biostatistical workflows, with specific verifiable examples and quantified gains in cycle time, throughput, or quality.
  • Ability to establish reliable, reproducible, compliant AI-assisted workflows with human-in-the-loop verification controls in an international GxP environment.
  • Ability to operate independently, set direction for others, resolve ambiguity without escalation, and own the technical quality of a multi-project portfolio.
  • Established reputation and sustained relationships in the external biostatistics, medical device, clinical trial, and regulatory communities, with independent contributions to the field.
  • Strong verbal and written communication, teamwork, and interpersonal skills with technical and non-technical audiences.
  • Strong scientific writing and editing skills, attention to detail, and scientific integrity.
Responsibilities
  • Independently develop statistical approaches for complex clinical protocols, including Bayesian and frequentist design selection, endpoint and estimand framing, hypothesis testing, power analyses, sample-size justification, randomization design and review, and adaptive or interim analysis strategies.
  • Serve as the final internal statistical authority for design decisions across owned studies and advise on program- and platform-level design trade-offs.
  • Serve Data Monitoring Committees and Data and Safety Monitoring Boards as the unblinded sponsor statistician.
  • Set the vision, standards, templates, and pre-specification approach for Statistical Analysis Plans and mock Tables, Listings, and Figures across the portfolio.
  • Review and approve Statistical Analysis Plans and mock Tables, Listings, and Figures authored by others.
  • Set the direction for clinical-trial data analysis and personally own the most complex or novel analytical problems.
  • Direct interim analyses, database-lock, and unblinding activities according to study requirements.
  • Manage a portfolio of at least 10 concurrent projects, own multiple business or functional areas, set priorities, sequence work, and allocate statistical effort.
  • Represent Biostatistics in core-team and program-level forums, shape evidence-generation strategy, set execution roadmaps, and manage timelines and stakeholder expectations.
  • Influence senior leadership as a strategic thought partner and translate statistical complexity into clear, actionable direction with clinical and business implications.
  • Lead meetings and set agendas for the biostatistics team.
  • Write or edit methods, results, and interpretation sections for regulatory submissions, compliance documents, scientific journals, and medical conferences.
  • Lead research to generate clinical evidence, including analyses of large clinical or administrative databases, systematic literature reviews, and meta-analyses.
  • Contribute independently to the scientific community through peer-reviewed publications, conference presentations, and methodological contributions.
  • Represent the organization in direct interactions with regulatory agencies, principal investigators, key opinion leaders, and external statisticians.
  • Address regulatory-authority questions on statistical design and analysis for pre-approval, post-approval, and post-market clinical follow-up studies.
  • Co-strategize with Data Management on data quality, consistency, scalability, and traceability.
  • Specify CDISC-aligned data structures, including SDTM and ADaM, and establish analysis-ready dataset specifications.
  • Set department-wide programming and analysis standards and implement them through personal example and departmental adoption.
  • Develop and own standard operating procedures and work instructions for standardization, validation, and quality control of analysis pipelines.
  • Set the biostatistics training curriculum and deliver training in biostatistical methodology and programming practices.
  • Provide technical leadership and career-development guidance to junior statisticians.
  • Oversee and direct external statistical vendors and contract research organizations.
  • Ensure activities comply with Good Clinical Practice, ISO 14155, ICH E9, ICH E6, and 21 CFR Part 812, and apply relevant FDA guidance on adaptive designs and Bayesian methods for medical-device trials.
Desired Qualifications
  • Surgical and robotic-assisted device clinical research experience.
  • Experience with SAS.
  • Experience with Python.

About the company

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 19% to $2.89 billion, with 16% procedure growth.
  • July 16, 2026 guidance projected 13.5%-15.5% da Vinci procedure growth for 2026.
  • Malaysia's 316,000-square-foot Penang plant starts 2028, adding 1,200 jobs by 2032.

What critics are saying

  • August 13, 2026 Ninth Circuit revived SIS monopolization claims against Intuitive.
  • February 26, 2026 ASC patent suit targets da Vinci repair and component refurbishing.
  • If courts force aftermarket openness, Intuitive's recurring instrument economics collapse within years.

What makes Intuitive Surgical unique

  • Da Vinci 5 reached 11,710 installed systems by June 30, 2026.
  • Intuitive sold 246 da Vinci 5 systems in Q2 2026.
  • September 2026 CE mark expanded da Vinci 5 cardiac procedures in Europe.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 0%
Yahoo Finance
Oct 1st, 2026
Intuitive Surgical down 30% in 2026, but Wall Street analysts stay bullish

Intuitive Surgical has lost nearly 30% year-to-date in 2026, making it one of healthcare's biggest losers. The stock fell over 40% by late July. Despite this decline, Wall Street remains bullish—24 of 32 analysts surveyed by S&P Global in September rated it a "buy" or "strong buy." The medical device maker faces several challenges. Growth is slowing whilst the stock trades at a forward price-to-earnings multiple over 33. Competition in China remains difficult, and the company now battles healthcare giants Johnson & Johnson, Medtronic, and Stryker in robotic surgical systems. The expiration of Affordable Care Act subsidies and rising GLP-1 drug usage have also impacted procedure volumes. However, the company's Asian revenue still jumped 20% year-over-year in Q2, suggesting these headwinds aren't insurmountable.

Yahoo Finance
Sep 17th, 2026
Intuitive Surgical, IonQ, and Accenture hold billions in net cash for growth

Investors seeking financial stability often look to companies with more cash than debt, as these businesses have greater flexibility for growth investments, buybacks, and dividends. Intuitive Surgical holds $5.22 billion in net cash. The robotic surgery pioneer achieved 20.7% annual revenue growth over the past two years, whilst its earnings per share increased 17.4% annually over five years. IonQ maintains $2.06 billion in net cash, representing 14.1% of its market capitalisation. The quantum computing company posted 181% annual revenue growth over two years and expects 163% growth next year. Accenture has $1.78 billion in net cash. The professional services firm employs approximately 774,000 people across more than 120 countries. Companies with strong balance sheets can navigate uncertain markets whilst pursuing expansion opportunities without the burden of significant debt obligations.

Yahoo Finance
Aug 23rd, 2026
Thermo Fisher vs Intuitive Surgical: which premium healthcare stock justifies valuation?

Thermo Fisher and Intuitive Surgical both delivered strong recent quarters, but their premium valuations rest on different foundations. Thermo Fisher's case depends on recovery in life sciences spending after the pandemic slowdown. The company's Life Sciences Solutions segment saw reported revenue climb 13% year-over-year, with organic revenue up 3%. The Analytical Instruments business returned to growth after nearly two years of weak demand, suggesting laboratory spending is normalising. Intuitive Surgical maintains its premium through business model strength. The company's non-GAAP gross profit margin reached 70.0%, whilst its non-GAAP operating margin expanded 330 basis points year-over-year to 42.1%. Recurring revenue streams constitute roughly 85% of total sales. Intuitive placed 468 da Vinci surgical units in fiscal Q2, marking 18% year-over-year growth, indicating continued hospital investment in robotic surgery platforms.

Yahoo Finance
Aug 19th, 2026
Abbott beats Q2 estimates with 13% sales growth as diagnostics surge 42%, while Intuitive Surgical posts 19% revenue rise

Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.

PR Newswire
Aug 17th, 2026
Intuitive leases 316,000-sq-ft facility in Penang to manufacture surgical instruments, create 1,200 jobs by 2032

Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.